Investor's Business Daily on MSN1d
Halozyme Stock Climbs Back After 2024 Sneak Peak As Earnings Loom
Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...
TOP RANKED ROSEN LAW FIRM Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIOA
Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ:BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...
Sandra Bullock And Brad Pitt Fans Targeted Via Social Media Scams
Scams involving celebrities or other famous people aren't really new - and are simply a modern take on the "Spanish Prisoner" or "Nigerian Prince" schemes ...
Investor's Business Daily on MSN11h
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Hims stock surged into a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. Please watch the video at ...
Why Eli Lilly Stock Popped on Thursday
Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...
Eli Lilly Stock Rises After Earnings Beat Forecasts
Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...
Eli Lilly Stock Rises After Profit, Outlook Top Expectations
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Yahoo Finance4d
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Analysts are bullish on the maker of weight-loss drugs Zepbound and Mounjaro, with 10 of the 11 analysts who follow the company and are tracked by Visible Alpha rating Eli Lilly stock as a "buy ...
Investopedia4d
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...